Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628379 | 0.96 | POLB (0.42) | POLBKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL789714 | 0.91 | — | — | |
| SCHEMBL16931558 | 0.86 | ADH1B (0.39) | ALDH1A1LMNA | |
| SCHEMBL4625897 | 0.86 | TAS1R3 (0.39) | POLBCA1CA2 | |
| SCHEMBL16628395 | 0.83 | CA12 (0.50) | POLBKMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL16931561 | 0.82 | ADH1B (0.39) | ALDH1A1LMNA | |
| SCHEMBL21064666 | 0.80 | — | — | |
| SCHEMBL17514080 | 0.80 | CA12 (0.52) | POLBKMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL16628562 | 0.78 | CA12 (0.50) | POLBKMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL1829144 | 0.78 | TAS1R3 (0.42) | POLBCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860170-B1 | PROCESS FOR PREPARING 4-HYDROXYBUTYL ACRYLATE | OSAKA ORGANIC CHEMICAL IND LTD (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-9670129-B2 | Process for preparing 4-hydroxybutyl acrylate | OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20150126766-A1 | PROCESS FOR PREPARING 4-HYDROXYBUTYL ACRYLATE | OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2860170-A1 | PROCESS FOR PREPARING 4-HYDROXYBUTYL ACRYLATE | Osaka Organic Chemical Ind., Ltd. (JP) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126766-A1 | PROCESS FOR PREPARING 4-HYDROXYBUTYL ACRYLATE | LTB4R2, LTA4H, LTB4R | POLB 2218/4885KMT2A 3962/4885NPC1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.